This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Encore Clinical, Inc., University of California. Active years: 2016.
Company Filing History:
1 out of 1 
1 out of 15,988 
Years Active: 2016
Title: David M Berryman: Innovator in Lung Cancer Prognostics
Introduction
David M Berryman is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of cancer research, particularly in developing prognostic tools for lung cancer. His innovative work focuses on utilizing molecular markers to improve patient outcomes.
Latest Patents
David M Berryman holds a patent for a multigene prognostic assay for lung cancer. This invention provides methods for determining a prognosis for lung cancer using a panel of eleven molecular markers. These markers include BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The markers are particularly useful in providing a prognosis for non-squamous non-small cell lung cancer (NSCLC) and are related to patient prognosis concerning 5-year overall survival outcomes.
Career Highlights
Throughout his career, David has worked with prestigious institutions, including the University of California and Encore Clinical, Inc. His work has been instrumental in advancing the understanding of lung cancer and improving prognostic assessments.
Collaborations
David M Berryman has collaborated with notable professionals in the field, including Michael Mann and David Jablons. These collaborations have contributed to the development of innovative solutions in cancer research.
Conclusion
David M Berryman's contributions to lung cancer prognostics through his patent and collaborations highlight his commitment to improving patient care. His work continues to influence the field of cancer research and offers hope for better prognostic tools in the future.